Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Altern Ther Health Med ; 30(5): 130-135, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38430173

RESUMEN

Background: Stable angina pectoris (SAP) is an ischemic heart disease caused by coronary artery stenosis, which usually occurs during physical activity or emotional excitement. For this type of angina pectoris, reducing the oxygen demand of the heart and increasing the coronary blood flow are the key goals of treatment. Objective: To analyze nicorandil's application effect and adverse reactions in patients with SAP. Methods: Sixty patients with stable angina pectoris admitted to our hospital from December 2020 to May 2022 were randomly selected and included in this study. They were divided into nicorandil group (n=30) and conventional group (n=30). The clinical efficacy, duration of chest pain, number of heart attacks per week, cardiac function indexes, improvement of exercise tolerance, occurrence of adverse reactions, and Seattle Angina Scale (SAQ) score were observed. Results: The effective rate of nicorandil group was 93.33%, which was much higher than that of conventional group (73.33%, P < .05). The results showed that the nicorandil group was significantly better than the conventional group in clinical efficacy, duration of chest pain, number of attacks per week, cardiac function index, improvement of exercise tolerance, occurrence of adverse reactions and SAQ score (P < .05). Conclusions: Nicorandil can improve the clinical symptoms of SAP patients, significantly reduce the duration and frequency of chest pain attacks, and enhance cardiac function indicators. It can be used as an effective drug choice to reduce the frequency and intensity of angina pectoris attacks and is worthy of wide clinical application.


Asunto(s)
Angina Estable , Nicorandil , Humanos , Nicorandil/uso terapéutico , Nicorandil/efectos adversos , Masculino , Femenino , Angina Estable/tratamiento farmacológico , Persona de Mediana Edad , Anciano , Resultado del Tratamiento , Vasodilatadores/uso terapéutico , Vasodilatadores/efectos adversos
2.
Hum Exp Toxicol ; 41: 9603271221077684, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35196174

RESUMEN

OBJECTIVE: Shenfu injection (SFI) is commonly used for cardiac dysfunction in China. Adenosine receptors have been reported to exert anti-fibrosis effects. The intent of this study was to evaluate that SFI attenuates cardiac fibrosis through activating of adenosine A2a receptor (A2aR) in rats with myocardial ischemia-reperfusion (MI/R). METHODS: Sprague Dawley male rats were randomly divided into five groups, nine rats in each group. Injections in all rat groups were carried out prior to reperfusion, and in the sham and MI/R groups, only vehicle was injected. Injections in the remaining group were as follows: 5 mL/kg in the SFI group; 15 mg/kg nicorandil in the A2R agonist group; and 5 mL/kg SFI plus 5 mg/kg MSX-3 in the SFI + A2aR antagonist group. Changes in cyclic adenosine monophosphate (cAMP) and the development of myocardial infarction and cardiac fibrosis were documented among the groups. Additionally, the levels of A2aR, collagen Ⅰ, collagen Ⅲ, fibronectin, and matrix metalloproteinase-9 (MMP-9) were measured. RESULTS: Following injection with SFI or nicorandil, the cAMP concentration, infarct area, and cardiac fibrosis induced by MI/R injury were significantly decreased (p < 0.05). Additionally, the levels of collagen Ⅰ, collagen Ⅲ, fibronectin, and MMP-9 were clearly suppressed by SFI or nicorandil when compared with the MI/R group (p<0.01). However, the protective effects of SFI were counteracted by MSX-3. A negative correlation between A2aR and collagen I and collagen III was found (p = 0.00). CONCLUSION: SFI activated the A2aR to reduce myocardial fibrosis caused by MI/R injury, which provided an underlying mechanism of action of SFI.


Asunto(s)
Antagonistas del Receptor de Adenosina A2/uso terapéutico , Antiarrítmicos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Fibrosis/tratamiento farmacológico , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Nicorandil/uso terapéutico , Receptor de Adenosina A2A/efectos de los fármacos , Animales , Antiarrítmicos/administración & dosificación , China , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/administración & dosificación , Humanos , Masculino , Nicorandil/administración & dosificación , Ratas , Ratas Sprague-Dawley
3.
Hum Exp Toxicol ; 39(12): 1700-1709, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32666843

RESUMEN

Methotrexate (MTX) is a widely used chemotherapeutic agent but its clinical use is challenged with different forms of toxicities including testicular injury. The aim of the current study was to evaluate the potential protective effect of potassium channel opener, nicorandil (NIC) (3 and 10 mg/kg/day) on MTX-induced testicular injury in a rat model. Rats were randomly divided into four groups (nine rats each) and treated for 2 weeks as follows: (I) normal control (CON group) received vehicle, (II) model group (MTX group) given MTX (20 mg/kg) single intraperitoneal (i.p.) injection dose on 11th day, (III) MTX + NLD group treated with NIC (3 mg/kg/day) orally for 2 weeks and MTX (20 mg/kg) single i.p. dose on 11th day, and (IV) MTX + NHD group treated with NIC (10 mg/kg/day) orally for 2 weeks and MTX (20 mg/kg) single i.p. injection on the 11th day. The testicular injury was assessed biochemically via serum testosterone, total antioxidant capacity, testicular oxidative stress parameters, P-glycoprotein, tumor necrosis factor-alpha, and interleukin-1ß. Furthermore, histopathological evaluation, endothelial nitric oxide synthase (eNOS) immunoexpression, and detection of p53 expression level using Western blotting were performed. Results showed that MTX induced testicular injury which was proved by both biochemical and histopathological evaluations. Our results concluded that NIC pretreatment attenuated MTX-induced testicular injury via significantly increased eNOS immunoexpression, antiapoptotic, anti-inflammatory, and antioxidant properties. Interestingly, NIC high dose is more protective than low dose.


Asunto(s)
Antimetabolitos Antineoplásicos/toxicidad , Metotrexato/toxicidad , Nicorandil/uso terapéutico , Donantes de Óxido Nítrico/uso terapéutico , Sustancias Protectoras/uso terapéutico , Testículo/efectos de los fármacos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Glutatión/metabolismo , Mediadores de Inflamación/metabolismo , Masculino , Malondialdehído/metabolismo , Nicorandil/farmacología , Donantes de Óxido Nítrico/farmacología , Óxido Nítrico Sintasa de Tipo III/metabolismo , Estrés Oxidativo/efectos de los fármacos , Sustancias Protectoras/farmacología , Ratas Wistar , Testículo/lesiones , Testículo/metabolismo , Testículo/patología , Testosterona/sangre , Proteína p53 Supresora de Tumor/metabolismo
4.
Medicine (Baltimore) ; 99(21): e20099, 2020 May 22.
Artículo en Inglés | MEDLINE | ID: mdl-32481277

RESUMEN

INTRODUCTION: Coronary microvascular dysfunction (CMVD), highly prevalent among patients with a mental disorder (anxiety or depression), is closely related to adverse cardiac events, including hospitalization, sudden cardiac death, and myocardial infarction. Shexiang Tongxin Dropping Pills (STDP), a traditional Chinese medicine, exerts endothelial protective function by anti-inflammation, anti-oxidative stress, and promoting blood circulation. STDP protects against CMVD in previous fundamental studies. The present trial is aiming at evaluating the effect of STDP on CMVD among depressed or anxious patients with non-obstructive coronary artery disease (NOCAD). METHODS AND ANALYSIS: Seventy-two depressed or anxious patients diagnosed with NOCAD combined with CMVD utilizing coronary artery angiography and stress cardiac magnetic resonance (CMR) will be recruited in the present study. These patients will be randomized into two groups, namely, Nicorandil group (Nicorandil combined with routine medicine), and STDP groups (STDP combined with routine medicine). The change of CMVD status by assessing absolute myocardial blood flow and myocardial reperfusion using stress CMR 3-month after discharge is defined as the primary endpoint. Major adverse cardiac events (MACEs), quality of life (QOL), and metal disorder improvement are defined as the secondary endpoints. Seattle angina questionnaire (SAQ) which is used to assess angina pectoris and QOL will be recorded at 1-, 3-, 6-, 9-, 12-month of follow-up. Seven-item Generalized Anxiety Disorder Scale (GAD-7) and 9-item depression module from the Patient Health Questionnaire (PHQ9) which utilized to evaluate anxiety and depression, respectively, will be recorded at 1-, 3-, 6-, 9-, 12-month of follow-up. This study will first evaluate the efficacy of STDP on CMVD among patients with a mental disorder and NOCAD, and discuss the potential mechanisms, providing therapeutic evidence for the STDP for these patients.


Asunto(s)
Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Vasos Coronarios/efectos de los fármacos , Medicamentos Herbarios Chinos/uso terapéutico , Ansiedad/complicaciones , Enfermedad de la Arteria Coronaria/complicaciones , Depresión/complicaciones , Femenino , Humanos , Masculino , Nicorandil/uso terapéutico , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto
5.
Undersea Hyperb Med ; 46(4): 483-494, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31509904

RESUMEN

The aim of this study was to establish the effect of combined therapy with hyperbaric oxygen (HBO2) therapy and verapamil, amlodipine or nicorandil on functional recovery and oxidative stress markers after ischemia in the isolated rat heart. The study included 48 rats (Wistar albino, male gender, eight weeks old, body weight 200±50g). All animals were exposed to HBO2 treatment over 14 days. Isolated heart rats were perfused by the Langendorff retrograde method at a constant coronary pressure of 70 cm H2O. After stabilization period the hearts were divided into the following groups: HBO2 group (animals exposed to only HBO2 preconditioning); HBO2 + verapamil; HBO2 + amlodipine; andHBO2 + nicorandil (animals pretreated with HBO2 and appropriate pharmacological agent). Afterward, the hearts in all groups were subjected to 20-minute global ischemia and 30-minute reperfusion. Parameters of heart function were registered, including maximum and minimum rate of pressure development, systolic and diastolic left ventricular pressure, heart rate and coronary flow. Levels of pro-oxidants such as index of lipid peroxidation, measured as thiobarbituric acid-reactive substances, nitrites, levels of superoxide anion radicals and hydrogen peroxide were determined in coronary venous effluent. Changes in cardiac tissue were evaluated by hematoxylin and eosin staining. Obtained results clearly indicate that blockage of calcium channel or the activation of adenosine triphosphate-sensitive potassium (KATP) in combination with HBO2 prevented ischemia/reperfusion-induced cardiac deleterious effects, thus contributing to improvement of functional recovery of the heart. However, future studies are certainly necessary for better understanding the mechanisms through which combination of these two maneuvers of preconditioning triggers cardioprotection.


Asunto(s)
Bloqueadores de los Canales de Calcio/uso terapéutico , Oxigenoterapia Hiperbárica , Precondicionamiento Isquémico Miocárdico/métodos , Isquemia Miocárdica/terapia , Daño por Reperfusión Miocárdica/prevención & control , Bloqueadores de los Canales de Potasio/uso terapéutico , Amlodipino/uso terapéutico , Animales , Presión Sanguínea/efectos de los fármacos , Terapia Combinada/métodos , Circulación Coronaria , Corazón , Frecuencia Cardíaca/efectos de los fármacos , Precondicionamiento Isquémico Miocárdico/efectos adversos , Peroxidación de Lípido , Masculino , Miocardio/patología , Nicorandil/uso terapéutico , Estrés Oxidativo , Ratas , Ratas Wistar , Recuperación de la Función , Verapamilo/uso terapéutico
6.
Acta Neurobiol Exp (Wars) ; 77(1): 57-67, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28379216

RESUMEN

Evidences suggest that the presence of chronic kidney disease (CKD) is associated with cerebrovascular diseases related cognitive decline in dialysis patients. As mitochondrial dysfunction is implicated in neurodegenerative disorders, we hypothesized that changes in brain mitochondria occur due to vascular calcification induced by renal failure and the opening of the mitochondrial potassium channel using nicorandil may prevent its dysfunction. Brain tissues from rats with vascular calcification were studied. Nicorandil (7.5 mg/kg b.wt.) was given either concomitantly or after the induction of calcification. The brain tissues were evaluated for antioxidant capacity, mitochondrial enzymes and oxidative phosphorylation efficiency along with the progression of calcification. The results suggested that renal failure, elevated the calcium, phosphorus product in the brain. The brain cytoplasm and mitochondrial fractions showed an elevated TBARS and a corresponding decline in the antioxidant enzymes, indicating a sev ere oxidative stress. The elevated brain mitochondrial enzymes like NADH dehydrogenase, and succinate dehydrogenase in the disease control groups, reversed to the near control level after nicorandil treatment. We observed that nicorandil was more effective when given after calcification. It reduced the biochemical alterations associated with calcium and phosphorous toxicity in the brain, by preserving mitochondria, the key target for treating neurodegenerative diseases.


Asunto(s)
Mitocondrias/efectos de los fármacos , Enfermedades Mitocondriales/tratamiento farmacológico , Nicorandil/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Calcificación Vascular/prevención & control , Complejo Vitamínico B/uso terapéutico , Animales , Aorta/patología , Calcio/metabolismo , Catalasa/metabolismo , Esquema de Medicación , Depuradores de Radicales Libres/metabolismo , Antígenos de Histocompatibilidad Clase I/metabolismo , Pruebas de Función Renal , Peroxidación de Lípido/efectos de los fármacos , Mitocondrias/metabolismo , Mitocondrias/ultraestructura , Enfermedades Mitocondriales/etiología , Nicorandil/farmacología , Fósforo/metabolismo , Ratas , Ratas Wistar , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/diagnóstico , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo , Calcificación Vascular/etiología , Complejo Vitamínico B/farmacología
7.
Turk Neurosurg ; 27(6): 884-893, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-27593840

RESUMEN

AIM: Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most important complication that effects the mortality and morbidity of patients with intracranial aneurysm. Today, the mechanisms of vasospasm are not understood in spite of experimental and clinical researches. The aim of our study was to investigate the effects of curcumin on vasospasm following SAH. MATERIAL AND METHODS: In this study, 64 rats (200-250 g weight) were divided into 7 groups. Group 1: having no treatment after SAH; Group 2: treatment with nimodipine after SAH; Group 3: treatment with nicorandil after SAH; Group 4: treatment with sildenafil citrate after SAH; Group 5: treatment with 150 mg/kg curcumin after SAH; Group 6: treatment with 300 mg/kg curcumin after SAH, Group 7: treatment with 600 mg/kg curcumin after SAH. The experimental SAH was induced by injection of autologous blood into the cisterna magna. After medical treatment, in the first hour, blood was taken for quantified the levels of TNF-α, IL-1ß and IL-6. Then, cerebrum and cerebellum were removed for analysis. Basilar artery luminal diameter was measured and apoptotic cell count was performed with tissue samples. RESULTS: Histopathological findings showed that, in sufficient dose, curcumin dilated the basilar artery beside anti-oxidant effect. CONCLUSION: Curcumin can be used for the treatment of vasospasm as a new medical drug.


Asunto(s)
Arteria Basilar/efectos de los fármacos , Curcumina/farmacología , Curcumina/uso terapéutico , Hemorragia Subaracnoidea/complicaciones , Vasodilatadores/uso terapéutico , Vasoespasmo Intracraneal/complicaciones , Vasoespasmo Intracraneal/tratamiento farmacológico , Animales , Apoptosis/efectos de los fármacos , Cerebelo/patología , Corteza Cerebral/patología , Interleucina-1beta/sangre , Interleucina-6/sangre , Masculino , Nicorandil/farmacología , Nicorandil/uso terapéutico , Nimodipina/farmacología , Nimodipina/uso terapéutico , Ratas , Citrato de Sildenafil/farmacología , Citrato de Sildenafil/uso terapéutico , Hemorragia Subaracnoidea/fisiopatología , Factor de Necrosis Tumoral alfa/sangre , Vasodilatadores/farmacología
8.
Kardiologiia ; 56(6): 26-31, 2016 06.
Artículo en Ruso | MEDLINE | ID: mdl-28290843

RESUMEN

The aim of the study to assess the influence of medicamentous therapy to the quality of life of ischemic heart disease patients with stable angina pectoris by activator potassium channels nicorandil in comparison with traditional therapy by isosorbide dinitrate. The study included 84 ischemic heart disease patients. Authors consider quality of life as an estimated category of state of the subject in an illness situation. The dynamic of physical and psychological components of quality of life are compared in ischemic heart disease patients under the treatment by nicorandil and isosorbide dinitrate. Indicators of quality of life, defined on the basis of a questionnaires of SAQ and GHQ supplementing an illness picture, are an multiple-factor criterion of an assessment of a condition of this category of patients. The benefits of nicorandil in influence on quality of life indicators were revealed in the study.


Asunto(s)
Angina Estable/tratamiento farmacológico , Angina Estable/psicología , Nicorandil/farmacología , Canales de Potasio/agonistas , Calidad de Vida , Vasodilatadores/farmacología , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nicorandil/uso terapéutico , Vasodilatadores/uso terapéutico
9.
Eur J Obstet Gynecol Reprod Biol ; 195: 27-30, 2015 12.
Artículo en Inglés | MEDLINE | ID: mdl-26476796

RESUMEN

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the Editor-in-Chief. The editors were alerted to the following concerning features of this trial: The submission date is impossible. Patients were recruited at 24 to 34 weeks (mean 31 w). 18% of participants delivered after 37 weeks. Average recruitment 26 per month. Recruitment ended September 2014 but the paper was received by journal on 23 October 2014. The second author, Sayyed T, is co-author of related retracted papers in BJOG. In view of these concerns we wrote to Dr Rezk who had no satisfactory explanation and declined to share the data. We have therefore decided to retract.


Asunto(s)
Nicorandil/uso terapéutico , Nifedipino/uso terapéutico , Trabajo de Parto Prematuro/tratamiento farmacológico , Tocolíticos/uso terapéutico , Adolescente , Adulto , Método Doble Ciego , Femenino , Enfermedades Fetales/inducido químicamente , Cefalea/inducido químicamente , Humanos , Embarazo , Complicaciones Cardiovasculares del Embarazo/inducido químicamente , Taquicardia/inducido químicamente , Resultado del Tratamiento , Adulto Joven
11.
J Cardiovasc Med (Hagerstown) ; 13(8): 511-5, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22609873

RESUMEN

OBJECTIVES: To study the protective mechanism of nicorandil on myocardial ischemia-reperfusion injury. METHODS: Fifty rats were randomly divided into five groups, four of which were operated on to produce myocardial ischemia-reperfusion. Nicorandil (5 mg/kg) was administrated by intravenous injection to three of the groups. The myocardial ultrastructure was observed by electron microscope. The expression levels of the antiapoptotic protein Bcl-2 and the pro-apoptotic protein Bax were detected by immunohistochemical staining with rhodamine 123. The mitochondrial membrane potential was detected by spectrophotometry. RESULTS: The activity of lactate dehydrogenase (LDH) and malondialdehyde (MDA) content was decreased and the activity of superoxide dismutase (SOD) was increased in the three nicorandil groups, compared with those in the group without nicorandil (P < 0.01, P < 0.05). The positive staining level of the expressed Bcl-2 was increased and the expressed Bax was decreased (P < 0.01) in the three nicorandil groups, compared with those in the group without nicorandil. The mitochondrial inner membrane potential was increased in the three nicorandil groups compared with that in the group without nicorandil (P < 0.05). CONCLUSION: A suitable level of nicorandil has a protective effect on rats' myocardial ischemia-reperfusion injury, and is mainly based on the opening of the mitochondrial KATP channel and the lowing of Ca overload.


Asunto(s)
Cardiotónicos/uso terapéutico , Daño por Reperfusión Miocárdica/prevención & control , Nicorandil/uso terapéutico , Animales , Cardiotónicos/farmacología , Evaluación Preclínica de Medicamentos/métodos , Ventrículos Cardíacos/metabolismo , L-Lactato Deshidrogenasa/sangre , Masculino , Malondialdehído/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Microscopía Electrónica , Daño por Reperfusión Miocárdica/metabolismo , Daño por Reperfusión Miocárdica/patología , Daño por Reperfusión Miocárdica/fisiopatología , Miocardio/ultraestructura , Nicorandil/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas , Ratas Sprague-Dawley , Superóxido Dismutasa/metabolismo , Proteína X Asociada a bcl-2/metabolismo
12.
Angiology ; 58(5): 636-9, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17906282
13.
Cardiovasc Drugs Ther ; 20(5): 377-86, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17124557

RESUMEN

INTRODUCTION: Recent advances in our understanding of the pathophysiological and molecular mechanisms involved in pulmonary arterial hypertension have led to the development of novel and rational pharmacological therapies. In addition to conventional therapy (i.e., supplemental oxygen and calcium channel blockers), prostacyclin or endothelin receptor antagonists have been recommended as a first-line therapy for pulmonary arterial hypertension. However, these treatments have potential limitations with regard to their long-term efficacy and improvement in survival. Furthermore, intravenous prostacyclin (epoprostenol) therapy, which is recommended by most experts for patients with New York Heart Association (NYHA) functional class IV, is complicated, uncomfortable for patients, and expensive because of the cumbersome administration system. Considering these circumstances, it is necessary to develop additional novel therapeutic approaches that target the various components of this multifactorial disease. CASE REPORT: In this short review, we present an overview of the current treatment options for pulmonary arterial hypertension and describe a case report with primary pulmonary hypertension. A male patient with NYHA functional class IV and showing no response to calcium channel blockers and prostacyclin exhibited significantly improved exercise tolerance and hemodynamics and long-term survival for more than 2.5 years after receiving an oral combination therapy of a phosphodiesterase type 5 inhibitor (sildenafil), phosphodiesterase type 3 inhibitor (pimobendan), and nicorandil. FUTURE PERSPECTIVE: We also discuss the background and plausible potential mechanisms involved in this case, as well as future perspectives in the treatment of pulmonary arterial hypertension.


Asunto(s)
Antihipertensivos/uso terapéutico , Hipertensión Pulmonar/terapia , Anticoagulantes/uso terapéutico , Bloqueadores de los Canales de Calcio/uso terapéutico , Diuréticos/uso terapéutico , Quimioterapia Combinada , Humanos , Masculino , Persona de Mediana Edad , Nicorandil/uso terapéutico , Donantes de Óxido Nítrico/uso terapéutico , Terapia por Inhalación de Oxígeno , Inhibidores de Fosfodiesterasa/uso terapéutico , Piperazinas/uso terapéutico , Purinas/uso terapéutico , Piridazinas/uso terapéutico , Citrato de Sildenafil , Sulfonas/uso terapéutico , Vasodilatadores/uso terapéutico
14.
Heart ; 90(2): 181-5, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14729792

RESUMEN

OBJECTIVE: To compare the effects of nicorandil (a hybrid ATP sensitive potassium channel (K+(ATP) channel) opener/nitric oxide donor) with those of isosorbide dinitrate (ISDN) on myocardial microcirculation and cardiac function in patients with acute myocardial infarction (AMI) who had undergone reperfusion treatment by direct balloon angioplasty. DESIGN: Double blind randomised study. PATIENTS: 60 patients with AMI in Killip class I. INTERVENTIONS: Patients were assigned into two treatment groups: a nicorandil group (n = 30) and an ISDN group (n = 30). Each drug was infused intravenously at 6 mg/h for 72 hours starting at admission and was administered directly to the treated coronary artery immediately after angioplasty. RESULTS: Compared with ISDN, nicorandil more frequently caused recovery of ST segment elevation just after reperfusion (15 of 27 (55.5%) in the nicorandil group v 5 of 26 (19.2%) in the ISDN group, p = 0.006). The nicorandil group had higher values of averaged peak velocity 40 minutes after reperfusion (mean (SD) 24.8 (13.3) cm/s v 16.0 (11.1) cm/s, p = 0.045) and higher values of regional wall motion of the infarcted area three weeks after onset of AMI (-1.78 (1.11) v -2.50 (1.04) SD/chord, p = 0.046). CONCLUSIONS: A combination of nicorandil drip infusion starting before reperfusion and intracoronary injection immediately after reperfusion is more effective than a similarly performed infusion of ISDN in preserving myocardial microcirculation in the reperfused AMI area. The nicorandil regimen resulted in better left ventricular regional wall motion.


Asunto(s)
Angioplastia de Balón/métodos , Dinitrato de Isosorbide/uso terapéutico , Infarto del Miocardio/terapia , Nicorandil/uso terapéutico , Vasodilatadores/uso terapéutico , Quimioterapia Adyuvante , Circulación Coronaria/efectos de los fármacos , Método Doble Ciego , Electrocardiografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/tratamiento farmacológico , Reperfusión Miocárdica/métodos , Estudios Prospectivos , Resultado del Tratamiento
15.
Jpn J Thorac Cardiovasc Surg ; 50(10): 430-4, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12428383

RESUMEN

OBJECTIVE: Warm ischemia is a major cause of cardiac allograft dysfunction in non-heart-beating donors (NHBDs). We evaluated the cardioprotective effects of nicorandil, an adenosine triphosphate-sensitive potassium channel opener, on the early posttransplant left ventricular (LV) function of hearts harvested from asphyxiated canine NHBDs. METHODS: Hypoxic cardiac arrest was induced in 12 donor dogs. In 6, nicorandil was administered intravenously at 100 micrograms/kg + 25 micrograms/kg/min after respiratory arrest and hearts were preserved with nicorandil-supplemented cardioplegic solution (nicorandil group). The remaining 6 did not receive nicorandil at any time during the experiment (control group). Hearts were orthotopically transplanted after a mean myocardial ischemic time of 4 hours. RESULTS: All 12 recipients were weaned from cardiopulmonary bypass without inotropic support. In the control group, posttransplant cardiac indices and left ventricular end-systolic pressure (LVESP) decreased significantly, while LV max-dP/dt and Tau increased over pretransplant values. No differences were seen in parameters between pretransplant and posttransplant values in the nicorandil group. Posttransplant cardiac indices, LVESP, and LV max + dP/dt were higher in the nicorandil group than in controls, while posttransplant LV max-dP/dt in the nicorandil group was lower. CONCLUSIONS: Our results indicate that pretreatment with nicorandil during hypoxic perfusion before cardiac arrest and subsequent preservation with nicorandil-supplemented cardioplegia ameliorates early posttransplant LV dysfunction of hearts harvested from asphyxiated NHBDs.


Asunto(s)
Cardiotónicos/uso terapéutico , Trasplante de Corazón , Nicorandil/uso terapéutico , Vasodilatadores/uso terapéutico , Animales , Perros , Complicaciones Posoperatorias
16.
Naunyn Schmiedebergs Arch Pharmacol ; 363(4): 407-13, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11330334

RESUMEN

Previous investigations have shown that nitric oxide donors and nicorandil can suppress allergic reaction. In the present study, the protective effects of nitroglycerin and nicorandil on cardiac anaphylaxis were examined. Presensitized guinea-pig hearts challenged with specific antigen caused a marked decrease in coronary flow (CF), left ventricular pressure (LVP) and its derivatives (+/-dp/dtmax), increase in heart rate, and prolongation of P-R interval. Nitroglycerin (300 nM) or nicorandil (100 microM) markedly increased the content of calcitonin gene-related peptide (CGRP) concomitant with a significant improvement of the cardiac dysfunction and alleviation of the extension of P-R interval. Nicorandil at a concentration of 100 microM also inhibited the sinus tachycardia and histamine release. The protection afforded by nitroglycerin was abolished by glibenclamide, a blocker of ATP-sensitive potassium channels, or by CGRP8-37, the selective CGRP receptor antagonist, or by pretreatment with capsaicin, which depletes endogenous CGRP. The inhibitory effect of nicorandil on cardiac anaphylaxis was abolished only by glibenclamide but not by pretreatment with capsaicin. These results suggest that nitroglycerin and nicorandil possess a protection of cardiac anaphylactic injury. The present study also suggests that the protective effect of nitroglycerin may be related to stimulation of CGRP release and opening the KATP channel, and that the effect of nicorandil is mainly due to the activation of the KATP channel.


Asunto(s)
Anafilaxia/prevención & control , Péptido Relacionado con Gen de Calcitonina/metabolismo , Corazón/efectos de los fármacos , Nicorandil/uso terapéutico , Nitroglicerina/uso terapéutico , Vasodilatadores/uso terapéutico , Animales , Capsaicina/farmacología , Circulación Coronaria/efectos de los fármacos , Interacciones Farmacológicas , Femenino , Gliburida/farmacología , Cobayas , Hemodinámica/efectos de los fármacos , Masculino , Canales de Potasio/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA